196 Results

People

  1. Drilon
    Drilon
  2. Aghajanian
    Aghajanian
  3. Abdel-Wahab
    Abdel-Wahab
  4. De Angelis
    De Angelis
  5. Fornier
    Fornier
  6. Motzer
    Motzer
  7. Zelenetz
    Zelenetz
  8. Abou-Alfa
    Abou-Alfa
  9. Basch
    Basch
  10. Fury
    Fury

Groups

  1. Department of Medicine (134)
  2. Solid Tumor Oncology Division (84)
  3. Hematologic Malignancies, Division of (48)
  4. Center for Hematologic Malignancies (41)
  5. Survivorship Research (25)
  6. GSK Faculty (23)
  7. Adult Leukemia (20)
  8. Thoracic Oncology (19)
  9. Genitourinary Oncology Service (18)
  10. Tow Center for Developmental Oncology (TCDO) (17)
  1. "dizziness"
Formats
  1. Journal Article (180)
  2. Review (12)
  3. Research Letter (2)
  4. Editorial (1)
  5. Guidelines (1)
Groups
  1. Department of Medicine (134)
  2. Solid Tumor Oncology Division (84)
  3. Hematologic Malignancies, Division of (48)
  4. Center for Hematologic Malignancies (41)
  5. Survivorship Research (25)
  6. GSK Faculty (23)

More Groups

People
  1. Alexander Drilon (10)
  2. Carol Aghajanian (7)
  3. Alan Ho (5)
  4. Andrew Zelenetz (5)
  5. Lisa De Angelis (5)
  6. Monica Fornier (5)

More People

Years
  1. 2025 (4)
  2. 2024 (21)
  3. 2023 (20)
  4. 2022 (8)
  5. 2021 (7)
  6. 2020 (18)

More Years

Publications
  1. Clinical Cancer Research (16)
  2. Journal of Clinical Oncology (13)
  3. Lancet Oncology (13)
  4. Blood (9)
  5. Annals of Oncology (8)
  6. Cancer (8)

More Publications

Publishers
  1. Elsevier Inc. (18)
  2. Elsevier Science, Inc. (18)
  3. Oxford University Press (17)
  4. American Association for Cancer Research (16)
  5. Nature Publishing Group (16)
  6. American Society of Clinical Oncology (13)

More Publishers

Results (196)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
    Research Letter

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A.; Sallman, D.; Patel, M.; Stevens, D.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • SWOG S1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
    Journal Article

    Shroff, R. T.; King, G.; Colby, S.; Scott, A. J.; Borad, M. J.; Goff, L.; Matin, K.; Mahipal, A.; Kalyan, A.; Javle, M. M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
    Journal Article

    Rathkopf, D. E.; Patel, M. R.; Choudhury, A. D.; Rasco, D.; Lakhani, N.; Hawley, J. E.; Srinivas, S.; Aparicio, A.; Narayan, V.; Runcie, K. D.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): Results from a randomised, open-label, phase 3 trial
    Journal Article

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    The Lancet Haematology (2025)

    Fulltext@MSK | Save
  • Adavosertib in combination with olaparib in patients with refractory solid tumors: An open-label, dose-finding, and dose-expansion Phase Ib trial
    Journal Article

    Hamilton, E. P.; Falchook, G. S.; Wang, J. S.; Fu, S.; Oza, A. M.; Imedio, E. R.; Kumar, S.; Ottesen, L.; Mugundu, G. M.; de Bruin, E. C.; more...
    Targeted Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2− breast cancer
    Journal Article

    Elias, A. D.; Staley, A. W.; Fornier, M.; Vidal, G. A.; Alami, V.; Sams, S.; Spoelstra, N. S.; Goodspeed, A.; Kabos, P.; Diamond, J. R.; more...
    npj Breast Cancer (2024)

    Fulltext@MSK | Save
  • Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: A phase 1 trial
    Journal Article

    Bullock, A. J.; Schlechter, B. L.; Fakih, M. G.; Tsimberidou, A. M.; Grossman, J. E.; Gordon, M. S.; Wilky, B. A.; Pimentel, A.; Mahadevan, D.; Balmanoukian, A. S.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer
    Journal Article

    Choudhury, N. J.; Lai, W. V.; Makhnin, A.; Heller, G.; Eng, J.; Li, B.; Preeshagul, I.; Santini, F. C.; Offin, M.; Ng, K.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial
    Journal Article

    Gupta, A.; O'Cearbhaill, R. E.; Block, M. S.; Hamilton, E.; Konner, J. A.; Knutson, K. L.; Potts, J.; Garrett, G.; Kenney, R. T.; Wenham, R. M.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Evaluating immune checkpoint blockade in metastatic castration-resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial
    Journal Article

    Nguyen, C. B.; Reimers, M. A.; Perera, C.; Abida, W.; Chou, J.; Feng, F. Y.; Antonarakis, E. S.; McKay, R. R.; Pachynski, R. K.; Zhang, J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save